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The limited commercial opportunity for bioprospecting for isolated pure natural compounds or their derivatives from plants for novel pharma-
ceuticals is discussed. A broad overview of the key research inputs involved in the commercialisation of indigenous medicinal plants as botanical
medicines is given to assist young researchers in contextualising research from an industry perspective, and to encourage university–industry col-
laboration. Compliance with the Biodiversity Act of 2004, and the regulations under this Act is stressed. The chain of research and development
(R&D) activities is brieﬂy described including ethnobotanical research, raw material supply, identiﬁcation of active compounds, extract develop-
ment, absorption studies, formulation development, in vitro, in vivo, and clinical safety and efﬁcacy studies, and protection of intellectual property.
Ultimately obtaining international marketing authorization for a novel botanical medicine is a lengthy and costly undertaking, with high risk of
failure. Elements of botanical medicine R&D can be applied to functional foods, novel foods and personal care products, which can reach the mar-
ket faster and with less risk than botanical medicines.
© 2011 SAAB. Published by Elsevier B.V. All rights reserved.
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This short communication for the South African Journal of
Botany's special edition on economic botany is intended to pro-
vide researchers, particularly young postgraduate students who
have little or no exposure to industry, with a broad overview of
the key research inputs involved in the commercialisation of in-
digenous medicinal plants as botanical medicines, and to afford
an insight into the many entry points where scientific research
contributes value along the commercial value chain from raw
material through to manufactured, marketed product. Informed
by the research inputs that contribute to the research and devel-
opment (R&D) of a botanical product, researchers interested in
the practical application and economic potential of their re-
search are encouraged to develop university–industry collabo-
rations early on to ensure they are addressing an identified⁎ Tel.: +27 21 7891243.
E-mail address: ngericke@mweb.co.za.
0254-6299/$ - see front matter © 2011 SAAB. Published by Elsevier B.V. All righ
doi:10.1016/j.sajb.2011.08.007market need as well as downstream regulatory requirements.
All researchers active in scientific work on useful plants of
South Africa should work closely with their institutions’ tech-
nology transfer offices to protect commercially important new
intellectual property prior to presentation or publication in the
public domain.
It is an essential prerequisite that all research on South African
plants must be fully compliant with local laws and regulations.
The United Nations Convention on Biological Diversity (CBD)
was one of the major outcomes of the Earth Summit in Rio de
Janeiro in June 1992, and as a signatory to the CBD South Africa
enacted the National Environmental Management: Biodiversity
Act (10 of 2004), known as ‘the Biodiversity Act’, or more popu-
larly as “NEMBA”. This law provides for the management and
conservation of South Africa's biodiversity including the protec-
tion of species and ecosystems that warrant national protection,
the sustainable use of indigenous biological resources, the fair
and equitable sharing of benefits arising from bioprospecting in-
volving indigenous biological resources, and for the establishmentts reserved.
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NEMBA defines “bioprospecting” in relation to indigenous bio-
logical resources as meaning any research on, or development or
application of, indigenous biological resources for commercial
or industrial exploitation, including:
(a) The systematic search, collection or gathering of such re-
sources or making extracts from such resources for pur-
poses of such research, development or application;
(b) The utilisation for purposes of such research or development
of any information regarding any traditional uses of indige-
nous biological resources by indigenous communities; or
(c) Research on, or the application, development or modifi-
cation of, any such traditional uses, for commercial or in-
dustrial exploitation.
Access and benefit-sharing regulations under NEMBA were
gazetted on 8 February 2008 (Regulations Gazette number
30739) (Government Gazette, 2008). These regulations make
a distinction between the ‘discovery’ phase of a bioprospecting
project, for early-stage academic or industrial research that is
being done prior to identifying a commercial opportunity, and
the ‘commercialisation’ phase when a commercial opportunity
has been identified, and further research is being done to ad-
vance a commercial venture. The Minister of Water and Envi-
ronmental Affairs is responsible for issuing permits for
bioprospecting and export purposes. Foreign nationals may
only apply for permits jointly with a South African collabora-
tor. An export permit must be obtained for the export of any in-
digenous biological resource when research on the material is
to be conducted outside of South Africa, or when the material
is to be commercialised outside of South Africa, and this export
must be deemed to be in the public interest. The regulations
also specify the criteria for material transfer agreements.
On the 8th of December 2009, HG&H Pharmaceuticals (Pty)
Ltd became the first company to be granted an integrated export
and bioprospecting permit, Permit No. IEP0001. This permit,
signed by the Minister of Water and Environmental Affairs, is
for research into, and export of, Sceletium tortuosum (L.) N.E.
Br. In applying for the permit the company demonstrated it had
successfully concluded the first South African prior informed con-
sent benefit-sharing agreement with indigenous knowledge
holders, through an agreement with the South African SanCouncil
signed on 21st February 2008. This agreement includes payment
over three years of up-front amounts prior to commercialisation
of product, and a defined percentage on all future income to be de-
rived from the commercialisation of Sceletium. The up-front
amounts and percentage royalty have not yet been made
public. In addition to its ethical approach in recognising the rights
of indigenous knowledge holders, the company had addressed en-
vironmental sustainability of wild plant resources by only utilising
cultivated Sceletium tortuosum for all research and export
purposes.
The Nagoya Protocol, a supplementary agreement to the CBD,
was adopted at the 10thmeeting of the Conference of the Parties to
the Convention on 29 October 2010 in Nagoya, Japan, and South
Africa became a signatory on 11May 2011. The Nagoya Protocoloutlines the legal procedures for access to genetic resources, ac-
cess to indigenous knowledge associated with genetic resources,
and the sharing of benefits arising from the utilization of genetic
resources and indigenous knowledge.
The prior informed consent of communities holding tradi-
tional knowledge must be obtained and benefits, both monetary
and non-monetary, arising from utilisation of that knowledge
must be shared with the indigenous knowledge holders. The
Protocol also obliges a user country to obtain formal informed
consent from a provider country prior to accessing indigenous
genetic resources or indigenous knowledge.2. Pharmaceuticals
Pharmaceuticals based on isolated pure natural compounds or
their derivatives represent the pinnacle of scientific, technical and
commercial value-addition for natural products, and the commer-
cial returns may be substantial: by definition a blockbuster phar-
maceutical generates US$1 billion or more in annual sales.
Important pharmaceuticals originally discovered from African
plants include physostigmine, a reversible acetylcholinesterase
inhibitor from Physostigma venenosum Balf. from Nigeria,
Cameroon and Gabon, used in treating Alzheimers Disease
(Orhan et al., 2009), and the vinca alkaloids, including vincris-
tine and vinblastine, that revolutionised the treatment of acute
leukaemia in children, derived from the Madagascar periwin-
kle, Catharanthus roseus (L.) G.Don. Although originally en-
demic to Madagascar (Foster, 2010), Catharanthus roseus is
now a pan-tropical ornamental and naturalised species.
Although most of the active ingredients in medicines have
historically been natural products from botanical and microbial
sources (Sneader, 1996), and natural products continue to form
a productive source of new drugs (Newman and Cragg, 2007;
Butler, 2008), the age of blockbuster drugs seems to largely
be over. The international pharmaceutical sector is presently
unable to deliver enough new products to market to generate
revenues sufficient to sustain its own growth, and nearly all
major drug developers are critically examining current R&D
practices (Kaitlin, 2010). FDA approvals of new drugs in the
United States reached a 24-year low in 2007 (Li and Vederas,
2009), and only three in 10 new products actually generate rev-
enues equal to or greater than the pharmaceutical industry R&D
costs (Kaitlin, 2010).
It would seem that bioprospecting activities by universities and
local research organizations, for new drug discovery, including
using ethnobotanically-directed approaches to bioprospecting,
have very little chance of achieving commercial success. None-
theless such groups would stand more chance of success if they
could pool resources and work towards a common goal: isolating,
characterising and validating lead compounds that are likely to be
suitable for development into pharmaceuticals or botanical medi-
cines that address unmet therapeutic needs for prevalent commu-
nicable diseases of Africa. Translational research – defined as the
movement of discoveries from basic research to application at the
clinical level (Ruttenberg et al., 2007) – is a growing field of re-
search, and the establishment of a South African centre of
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participate in pharmaceutical innovation.
3. Botanical medicines
Medicinal plants with a history of traditional use may be com-
mercialised as standardised plant extracts that are formulated into
liquid or solid oral dosage forms as polymolecular botanical med-
icines (also known as phytomedicines). The intended use of such
products is to prevent, treat or mitigate disease, and hence the use
of the word “medicine” as opposed to the term “dietary supple-
ment”which is not intended to prevent, treat, mitigate or diagnose
any disease condition. In December 2005, the German Federal In-
stitute for Drugs and Medical Devices (BfArM, Bonn) approved
a new license for the use of a proprietary extract of the root of the
South African medicinal plant Pelargonium sidoidesDC., (EPs®
7630), known in Germany by the trade name Umckaloabo®, as a
medicine (Conrad et al., 2007). The value of a registered botani-
cal medicine may be considerable: the liquid botanical medicine
Umckaloabo® has been reported to have had an annual turnover
in Germany alone in 2006 of €80,000,000 (Brendler and Van
Wyk, 2008). The commercial success of this product is due to
many convergent factors, including more than fifteen years of
major investment in scientific and clinical research addressing a
clearly defined unmet market need, and generating sufficient clin-
ical safety and efficacy data to get regulatory approval, astute
marketing that wove an intriguing story around the plant, solid
branding, and the use of an inexpensive wild plant resource that
would prove suited to new crop development. Although this in-
ternational success story based on a South African (and Lesotho)
plant was realised by a German company, it has provided a clear
example to South African researchers and South African compa-
nies of what can be achieved with well-directed value-addition.
The following annotated list is a broad outline of key elements
in the chain of research and development activities that add value
to a raw botanical product. Not all the described activities are nec-
essary for the successful beneficiation of a particular raw materi-
al, and the list is not intended to serve as a definitive and
exhaustive product development template. Further it will be evi-
dent that the R&D activities described are not necessarily done
sequentially, and many activities can be done in parallel. Key
entry points for protection of intellectual property through patents
are highlighted. A clearly articulated strategy for the protection of
hard intellectual property (i.e. patents) and soft intellectual prop-
erty (i.e. trademarks and copyright), and/or trade secrets, should
form an integral part of any botanical ingredient R&D plan.
While the R&D elements described below are for the develop-
ment of a botanical medicine, there is considerable overlap with
the requirements for products intended as dietary supplements,
nutraceuticals, or functional foods.
3.1. Ethnobotany
A thorough understanding of the historical and extant uses
of the plant by indigenous people and other rural communities
is essential to the discovery phase of a botanical medicines pro-
ject. Desktop literature research is a useful departure point, butthis should be supported with original field research. Ethnobo-
tanical research, properly planned and formally documented,
can provide a wealth of convergent information including pre-
liminary indications of safety, efficacy, doses, methods of prep-
aration, duration of use, use in pregnancy and use in children.
Ethnobotanical research can provide a platform for future re-
search opportunities, establish ownership of upstream and
downstream intellectual property, and identify beneficiary com-
munities for negotiating future benefit-sharing agreements. For
example, a benefit-sharing agreement between the South Afri-
can San Council and HG&H Pharmaceuticals (Pty) Ltd signed
on 21 February 2008 recognised that in terms of the literature
and oral tradition, the San were the primary indigenous knowl-
edge holders of the South African plant Sceletium tortuosum.
Ethnobotanical research conducted in the Namaqualand com-
munities of Nourivier and Paulshoek contributed useful infor-
mation on extant uses of Sceletium tortuosum, and the
contribution of these two communities was recognised by the
South African San Council through agreements between the
South African San Council and the two communities, signed
on 30 June, 2008.
Botanical voucher specimens accompanying ethnobotanical
anecdotes must be prepared and retained, and a formal botani-
cal determination of the voucher specimens should be undertak-
en by a taxonomist experienced in the species of interest.
Global Positioning System (GPS) readings should be taken
wherever possible to precisely describe the locality where spec-
imens are collected, and where local participants are inter-
viewed. The requirement of prior informed consent of local
research participants needs to be addressed.
3.2. Raw material
The plant species, and the plant part, selected for research
should either be sufficiently abundant in the wild to be amenable
to ecologically sustainable wild harvesting or ‘wild crafting’, or
have characteristics that indicate likely suitability for commercial
propagation and production. A full biosystematic study will
be invaluable in delineating the geographical distribution of the
species of interest, and describing the range of phytochemical
variability found within the species.
The potential for providing a commercial incentive the de-
structive harvesting of bark from trees, as seen with Prunus afri-
cana (Hook.f.) Kalkman in Cameroon where the bark is used to
produce extracts for treating benign prostatic hypertrophy, indi-
cates that bark should be avoided as a focus for botanical medi-
cine R&D, even if a business case can be made for future
commercial plantations. For wild-crafting, the resource size and
sustainability will need to be researched, and a supply chain ulti-
mately developed and managed. Properly managed and moni-
tored, wild-crafting, or a combination of wild-crafting and local
plantings can create jobs in rural areas and make a significant con-
tribution to improving rural livelihoods. A successful phased ap-
proach beginning with sustained-yield wild-harvesting followed
by the establishment of smallholder plantings has been used by
Unilever in for the production of edible oil from the seeds of
Allanblackia floribunda Oliv. in Ghana, Nigeria and Tanzania.
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tocols need to be developed, plant diseases studied, pollination bi-
ology understood, and factors influencing the production of
biomass studied. Qualitative and quantitative analytical methods
will be required to monitor the production of the active com-
pound/s of interest, and assist in selecting high-yield, high-biomass
plants, and determine the optimal season for harvesting. Plant bree-
der's rights may be applied for to protect specific cultivars of inter-
est. Understanding the phytochemical variability of the plants will
assist in the development of raw material quality standards.
Harvesting, post-harvesting and storage protocols need to be de-
veloped that preserve the raw material and its active compound/s,
prolong the raw material shelf-life and minimize microbial content
and microbial growth. It is possible to patent novel harvesting and
post-harvesting protocols, for example the process for harvesting
and drying the stems of Hoodia Sweet ex Decne (Meeuse and
Povey, 2008).
Sampling and analysing the stored raw material over time
for microbial content, and for the stability of the phytochemi-
cals of interest allows the establishment of the shelf-life for
the raw material. A detailed Certificate of Analysis (COA)
adds value to packaged botanical raw material, and should in-
clude as a minimum the botanical identity, source of the mate-
rial, source of the seeds, date of harvest, content of active/s and
analytical method used to determine this, microbiology, includ-
ing pathogenic bacteria, and results for analyses of heavy
metals, aflatoxins, and pesticide residues.3.3. Extract
An extract, preferably a standardised extract whereby the ac-
tive or putative active compound or compounds are present
within specified limits, adds considerable value to the original
botanical raw material, depending mainly on the quality of
the safety and efficacy data generated for the extract, and the
degree of protection afforded by the associated hard and soft in-
tellectual property. Extraction protocols need to be developed
which adequately extract the compounds of interest, and at
the same time represent as much of the overall plant chemistry
as required to comply with the regulatory specifications of a bo-
tanical medicine. Extract process development and optimisation
will need to be researched and a techno-economic model made
to quantity the cost of the process. The extraction process may
be suitable for patenting if sufficiently novel and inventive, for
example the patent position on the extraction of Hoodia (Van
Heerden et al., 2002).
The identification of an active or putative active compound, or
group of compounds, is the key to the development of a standar-
dised plant extract. The compounds selected may already be
known from the literature, or they may be novel, or novel applica-
tions may be found for known compounds. Cyclopia genistoides
(L.) R.Br., for example, contains appreciable concentrations of
the known xanthonemangiferin (Joubert et al., 2008).Mangiferin
has interesting central nervous system (CNS) activity (Jung et al.,
2009), and is also bioavailable (Li and Bi, 2005), providing a ra-
tional basis from desktop studies for the selection of mangiferinas an active compound for standardising extracts of Cyclopia
genistoides intended for CNS applications.
Active compounds may be found through a process of bioas-
say-directed fractionation using in vitro and/or in vivo models.
The use of the pregnane glycoside P57 fromHoodiawas patented
as an appetite-suppressing molecule (Van Heerden et al., 2002)
and this putative active compound has been used to standardise
Hoodia extracts that went into clinical research. In Sceletium,
mesembrine and related compounds were found to be selective
serotonin uptake inhibitors, and the pure compounds, synthetic
analogues, and extracts of Sceletium tortuosum standardised to
the content of these compounds were patented for their applica-
tion in treating mental health conditions (Gericke and Van
Wyk, 1999). More recently the application of the sesquiterpenoid
siphonochilone, and extracts containing siphonochilone from
Siphonochilus aethiopicus (Schweinf.) B.L. Burtt have been pat-
ented for application of the anti-inflammatory activities in formu-
lations treating asthma and allergic conditions (Horak et al.,
2009). Depending on the degree of novelty, inventive step in-
volved, and intended application, the merits and expense of a pat-
ent position should always be carefully considered for active
compounds and the extracts standardised to these active
compounds.
The level of accreditation of the facility that the extract is
made in, for example at a certified EU-Good Manufacturing
Practice facility, adds value to the extract. A detailed Certificate
of Analysis adds value to packaged extract, and should include
as a minimum the botanical identity of the original raw material,
extraction facility, batch number and date,solvent system used,
ratio of the plant: extract, solvent residues, concentration of
marker or active compound/s, and the analytical method used
to determine this. Microbiology, including pathogenic bacteria,
and results for analyses of heavy metals, aflatoxins, and pesticide
residues should also form part of the COA. The stability of the
extract, in the packaging intended for the market, should be mon-
itored on an ongoing basis to determine the shelf-life.
3.4. In vitro and in vivo studies
Pre-clinical evaluation of extract safety should be done in-vitro,
including cytotoxicity, mutagenicity, cardiotoxicity, and acute and
sub-chronic safety studies at appropriate doses should be done in-
vivo, according to internationally accepted protocols. The use of
accredited laboratories will enhance the credibility and value of
the results, particularly for studies intended to support a regulatory
submission.
In vitro absorption studies may be useful to demonstrate that
the compound/s of interest are in fact absorbed, and thus likely
to be bioavailable, and to identify where along the gastrointes-
tinal tract they are best absorbed. More valuable will be in vivo
research following the concentration and fate of key active/s
after a defined dose administered by the intended route of ad-
ministration, in absorption, distribution, metabolism and excre-
tion studies (ADME).
Placebo-controlled studies evaluating the efficacy of one or
more dose of standardised extract can add value if the results
are positive, and can provide supporting evidence for a patent
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use of plant material to an animal model may be problematic,
and dose-finding studies before a formal animal efficacy
study should be considered as a preliminary exercise.
3.5. Pharmaceutics
Before progressing with clinical trials in humans, it will be
necessary to give attention to the development of the formulation
to be used, for example tablets, capsules, tincture, syrup. For clin-
ical trials the facility manufacturing the formulation should be
suitably accredited by the regulatory authority: in South Africa
the facility should have current Good Manufacturing Practice
(GMP) certification from the Medicines Control Council. The
hardness, friability, and dissolution will need to be studied for
solid dosage forms. The stability of the formulation, and of the ac-
tive compound in the formulation, should be studied over time to
determine the shelf life of the finished unit of product. Consider-
ation should be given to the possibility of patenting the formula-
tion and its application if sufficiently novel and inventive, for
example food bar and drink formulations that provide nourish-
ment in addition to a defined amount of appetite-suppressing
P57 from Hoodia (Abrahamse et al., 2008).
3.6. Clinical trials
Indigenous medicinal plants are widely utilized in Africa
largely in an unprocessed form, mostly without scientific evi-
dence for safety and efficacy. The highest level of scientific
value addition to a manufactured botanical medicine is clinical
proof of safety, tolerability and efficacy in double-blind rando-
mised, placebo-controlled clinical trials, preferably conducted
on formulations of standardised extracts. Clinical studies should
be conducted in accordance with International Conference on
Harmonisation (ICH) guidelines for Good Clinical Practice
(GCP) in clinical trials and in full conformity with the fourth re-
vision (1996) of the Declaration of Helsinki. In South Africa
the clinical trial protocol, and patient informed consent document
must be approved by an independent ethics committee and by the
Medicines Control Council of South Africa prior to start of the
study, and a clinical trial registration number obtained. Because
of the high cost of a clinical trial, and its future value, it is advis-
able to work with clinicians with considerable clinical trial expe-
rience, and to develop a clinical trial protocol with the
participation of a statistician to ensure that the design of the clin-
ical trial, and the number of volunteers enrolled in the study, are
amenable to statistical analysis.
Only a handful of South African botanical medicines have
been evaluated for safety or efficacy by placebo-controlled clini-
cal studies: Pelargonium sidoides, Harpagophytum procumbens
(Burch.) DC. ex Meisn., Hoodia gordonii (Masson) Sweet ex
Decne, Sceletium tortuosum, and Sutherlandia frutescens (L.)
R.Br. The results of the controlled clinical trials on standardised
extracts of Hoodia and Sceletium have still to be published by
the sponsors of these trials.
While single studies are valuable, multiple studies on a botan-
ical medicine are amenable to meta-analysis and review by theCochrane Collaboration which conducts systematic reviews of
all relevant randomized controlled clinical trials. A positive
Cochrane review provides highly credible evidence for efficacy.
A Cochrane review of herbal medicine used for low back pain
found two high-quality clinical trials utilizing Harpagophytum
procumbens, and found strong evidence for short-term improve-
ments in pain and rescue medication utilization for daily doses
standardized to 50 mg or 100 mg harpagoside with another
high-quality trial demonstrating relative equivalence of the Har-
pagophytum to 12.5 mg per day of the pharmaceutical anti-in-
flammatory rofecoxib (Gagnier et al., 2007). A Cochrane
review of eight randomised clinical trials on Pelargonium
sidoides extract (EPs® 7630) found that it was effective in resolv-
ing all symptoms in the common cold and sinusitis in adults, and
in relieving symptoms of acute bronchitis in two out of three pae-
diatric studies (Timmer et al., 2008).
4. Marketing authorization
The legal and regulatory issues to be addressed before market-
ing botanical medicines on local and international markets are
complex and constantly evolving. It is essential to understand
the regulatory requirements for botanical medicines in the terri-
tories of potential market interest at the outset. Research informed
by knowledge of regulatory requirements will have a far greater
chance of being commercialised. With university–industry col-
laboration, the industry partner will typically brief the academic
partner on the regulatory requirements for the territory of interest,
and ensure that such requirements are met when approving con-
tract research protocols.
The South African regulatory requirements for the registration
of products derived from indigenous South African medicinal
plants are unfortunately not yet clear. The government has taken
steps towards the official recognition and institutionalisation of
African Traditional Medicine, including the establishment, in
2006, of a Directorate of Traditional Medicine to co-ordinate
and manage initiatives regarding African Traditional Medicine
within the Department of Health. Through the enactment of the
Traditional Health Practitioners Act 22 of 2007, a legal framework
was created to give formal recognition to traditional health practi-
tioners and to establish an interim Traditional Health Practitioners’
Council of South Africa with wide powers to ensure that health
care services provided by traditional practitioners are efficient,
safe and of a high quality (Rautenbach, 2011). In spite of these re-
cent developments there are presently no regulations in place in
South Africa for the registration of African Traditional Medicine,
whether in crude or minimally processed form, or in the form of
manufactured products. It can be expected that such regulations
will eventually be forthcoming. In its Draft Policy on African Tra-
ditional Medicine in 2008, the Department of Health declared :
“Most importantly in recognition of the reality that the majority
of South African people still use and continue to rely on African
Traditional Medicine for their primary healthcare needs, there is
a need for a policy to institutionalise and regulate African Tradi-
tional Medicine.” (Department of Health, 2008).
The Medicines Control Council of South Africa (MCC) is the
statutory body, established in terms of Act 101 of 1965, the
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regulation of all medicines in South Africa, including botanical
medicines. The evaluation of botanical medicines for safety, effi-
cacy and quality fall under the African Traditional Medicines
Committee of the MCC if the products are based on medicinal
plants utilized in African Traditional Medicine, and by the Com-
plementary Medicines Committee of the MCC if the products are
based on medicinal plants from other traditions, including Tradi-
tional Chinese Medicine, Ayurveda, Unani Tibb, and Western
herbal medicine. While applications for more than 11 800 com-
plementary medicines have been submitted for evaluation by
the Complementary Medicines Committee (Thakkar, 2011), it
is not yet known how many have been evaluated, or how many
have been given formal marketing authorization. At present
most companies are going directly to market in South Africa
with botanical medicines after simply notifying the Complemen-
tary Medicines Committee of this intention through submission
to the MCC of an abridged registration dossier.
In the essentially unregulated South African market for pro-
cessed and raw botanical medicines there are a plethora of prod-
ucts which have not been formally evaluated by the Medicines
Control Council for safety, quality, or efficacy. In this chaotic
environment the few companies investing in serious scientific
research and development are at a considerable disadvantage
to companies making exaggerated and irresponsible health
claims for products of unknown safety, efficacy or quality.
While the South African regulatory environment is not yet
clear, the pinnacle of commercial value-addition that a South
African botanical medicine can achieve is being granted a mar-
keting authorisation in a country with a major herbal market.
This marketing authorization is based on the evaluation of a
comprehensive dossier outlining the full historical and current
uses, and scientific and clinical evidence demonstrating safety,
efficacy and quality. The 2005 approval allowing for the use of
Pelargonium sidoides extract (EPs® 7630) as a medicine in
Germany, the country with largest herbal market in the Europe-
an Union, (Conrad et al., 2007) must thus be seen as a major
scientific and commercial achievement.
5. Conclusion
The development of a new botanical medicine from a South
African plant, exemplified by Pelargonium sidoides extract
(EPs® 7630) by the German company Dr. Willmar Schwabe
GmbH. & Co., is an expensive and arduous undertaking, and re-
alistically will take not less than five to seven years as a minimum,
and more likely at least double this time. Although the financial
rewards may ultimately be high, product development intended
for international markets is a costly high risk endeavor — as
evidenced by the disappointing failure of two multinational
companies, Pfizer, and subsequently Unilever, to commercial-
ise products from Hoodia gordonii (Vermaak et al., 2011). The
reasons why Unilever abandoned its expensive Hoodia re-
search and development programme have to date not been
made public.
While the R&D elements described above are required for
the development of a botanical medicine, there is considerableoverlap with the R&D requirements for products intended as di-
etary supplements, nutraceuticals, or functional foods. For these
categories of products, where no formal biomedicinal claim is
allowed, safety established from history of use as well as pre-
clinical and clinical evidence of safety is the major regulatory
concern, rather than pharmacological and clinical proof of effi-
cacy. The regulatory barriers to market entry are relatively low
for novel foods and functional foods, especially for those novel
foods with well-established historical as well as extant use.
This is evidenced by the European Commission Decision
2008/575/EC of 27 June 2008 authorizing the placing on the
market of baobab dried fruit pulp as a novel food ingredient
under Regulation (EC) No 258/97 of the European Parliament
and of the Council (European Commission, 2008), and the
granting in 2009 of Generally Regarded As Safe (GRAS) status
for baobab pulp in USA for use as an ingredient in blended fruit
drinks and fruit cereal bars up to a level of 10% and 15% re-
spectively (FDA, 2009). Considerable research opportunities
thus exist to discover novel and useful biological activities for
already-approved novel foods, allowing the early application
of these research results in functional food products. Similarly,
there are major opportunities to fast-track the research and de-
velopment of novel skin care and hair care products from
South African plants having biological activities and/or fra-
grances suitable for application in the rapidly growing natural
personal care products industry.References
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